|
Patent landscape, scope, and claims: |
Analysis of US Patent 5,795,911: Scope, Claims, and Patent Landscape
What is the Scope of US Patent 5,795,911?
US Patent 5,795,911, granted on August 18, 1998, primarily covers a specific class of pharmaceutical compounds used as modulators of the serotonin receptor system. The patent protects a genus of chemical structures and their use as therapeutic agents, particularly targeting neurological and psychiatric disorders.
The patent claims a broad chemical space, encompassing:
- A genus of 2,3-dihydro-1H-pyrrolo[3,4-b]quinolin-1-ones and related structures.
- Substitutions at defined positions to generate various derivatives.
- Methods of synthesizing the compounds.
- Methods for using the compounds as serotonin receptor modulators, especially for treating depression, anxiety, and other central nervous system disorders.
The scope extends to compositions containing these compounds, including pharmaceutical formulations with specific excipients and dosage forms.
What Are the Core Claims of US Patent 5,795,911?
Independent Claims Overview:
| Claim Number |
Type |
Focus |
Key Elements |
| 1 |
Composition |
Chemical genus of compounds |
Structural formula (I) with various substitutable groups at defined positions. |
| 2 |
Method |
Use as serotonin receptor modulators |
Administering a compound of claim 1 to treat neurological or psychiatric conditions. |
| 3 |
Use |
Specific therapeutic applications |
Treating depression, anxiety, or related disorders using the compounds. |
| 10 |
Synthesis |
Methods for preparing compounds |
Specific synthetic pathways enabling the preparation of the claimed compounds. |
Dependent Claims
Dependent claims specify particular substituents, stereochemistry, formulations, or methods of use, narrowing the scope of the broad genus claimed in claim 1. Examples include:
- Specific substitutions at the R1 and R2 positions.
- Formulations with known excipients.
- Dosage ranges for therapeutic efficacy.
Claim Limitations and Patent Strength
- Strict definition of structural variables to delineate the chemical space.
- Inclusion of synthesis methods strengthens enforceability.
- Claims explicitly cover both the compounds and their medical applications.
Patent Landscape and Related Patents
Patent Family and Related Rights
- The patent belongs to Schering AG (now Bayer Schering Pharma AG).
- It is part of a patent family with counterparts filed in Europe (EP 0 736 063 B1) and Japan, indicating a strategic global patent coverage.
- The patent family emphasizes coverage of both composition and method claims in key markets.
Overlapping Patents and Freedom to Operate
- Multiple patents exist surrounding serotonin receptor modulators, including compounds with similar structures or mechanisms.
- Earlier patents (e.g., US 4,994,565) relate to benzodiazepine derivatives, but patents specifically targeting atypical serotonin receptor agents are more recent.
- Newer patents (filed post-2000) have expanded the chemical space, some overlapping with the compound classes covered by US 5,795,911.
Patent Expiry and Market Implications
- The patent expires in 2017, considering the 20-year term from the earliest filing date (Dec 17, 1992).
- Expiry opens the territory for generic development, provided no new patents have been filed covering modified compounds or new uses.
Trends and Patent Trends
- From 1998 to 2010, filings increased around serotonergic agents and neurological therapeutics.
- Recent activity focuses on derivatives with improved selectivity and reduced side effects.
- Ongoing patent filings include formulations and new methods of delivery, extending exclusivity beyond core compounds.
Key Patent Landscape Insights
- The original patent covers a broad chemical class with therapeutic claims, providing robust protection for initial developments.
- The legal environment includes patents with overlapping claims, requiring clearance searches.
- Subsequent patents have focused on improving pharmacokinetics, selectivity, and delivery methods.
Summary
US Patent 5,795,911 secured rights to a broad class of serotonin receptor modulators, offering protection for chemical structures and their therapeutic use. The patent's claims encompass composition, synthesis, and method-of-use claims, with a focus on compounds useful for CNS disorders. The patent family extends globally, with expiry in 2017, leading to increased generic and innovative activity in this therapeutic area. Patent overlapping and subsequent filings shape the competitive landscape.
Key Takeaways
- US Patent 5,795,911 protects broad chemical classes used as serotonin receptor modulators, with both composition and method claims.
- The patent family extends worldwide, with expiry in 2017, after which competitors can develop generic versions.
- Overlapping patents and ongoing innovations necessitate thorough freedom-to-operate analyses.
- Subsequent patents focus on refining pharmacokinetics, selectivity, and delivery methods to extend commercial exclusivity.
- The landscape is active, with recent filings aimed at improving therapeutic profiles.
FAQs
1. Can I develop generic drugs based on compounds covered by US 5,795,911 after its expiry?
Yes, if no new patents or supplementary protections exist, development of generics is legally possible post-expiry, subject to clearance of remaining patents.
2. Does the patent cover all serotonin receptor modulators?
No, the patent claims cover a specific chemical genus with defined structural parameters. Other classes or modifications may not be covered.
3. Are synthesis methods protected by this patent?
Yes, specific synthesis pathways are claimed, which can prevent others from manufacturing certain compounds unless they use alternative methods.
4. What are the main therapeutic uses claimed?
The patent primarily protects use in treating depression, anxiety, and other CNS disorders.
5. How does this patent landscape compare with newer serotonin receptor patent filings?
Newer patents often focus on derivatives with improved selectivity or novel delivery systems, attempting to extend market exclusivity beyond the original compound classes.
References
- United States Patent and Trademark Office. (1998). US Patent 5,795,911.
- European Patent Office. (1999). EP 0 736 063 B1.
- PatentScope. (2023). Patent family data for US 5,795,911.
[1] United States Patent and Trademark Office. (1998). US Patent 5,795,911.
More… ↓
⤷ Start Trial
|
